Swiss National Bank Has $1.84 Million Position in RxSight, Inc. (NASDAQ:RXST)

Swiss National Bank lifted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 2.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,700 shares of the company’s stock after purchasing an additional 1,300 shares during the period. Swiss National Bank’s holdings in RxSight were worth $1,843,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. RiverPark Advisors LLC lifted its position in shares of RxSight by 70.0% in the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after buying an additional 275 shares during the last quarter. HighTower Advisors LLC boosted its position in RxSight by 7.3% during the third quarter. HighTower Advisors LLC now owns 13,256 shares of the company’s stock worth $369,000 after purchasing an additional 899 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of RxSight by 3.0% in the third quarter. Bank of New York Mellon Corp now owns 106,203 shares of the company’s stock valued at $2,962,000 after purchasing an additional 3,132 shares during the last quarter. Clarus Group Inc. bought a new position in shares of RxSight in the fourth quarter valued at about $202,000. Finally, Thompson Davis & CO. Inc. acquired a new stake in shares of RxSight during the 4th quarter worth about $212,000. 78.78% of the stock is owned by institutional investors.

RxSight Stock Up 0.9 %

RXST opened at $61.15 on Friday. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -48.53 and a beta of 1.21. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The company has a 50-day simple moving average of $55.26 and a 200 day simple moving average of $46.93.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). The firm had revenue of $29.51 million for the quarter, compared to the consensus estimate of $27.56 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The business’s revenue was up 68.7% on a year-over-year basis. During the same period last year, the company posted ($0.42) EPS. Sell-side analysts anticipate that RxSight, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at RxSight

In other news, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $56.37, for a total transaction of $563,700.00. Following the completion of the transaction, the chief financial officer now owns 13,691 shares of the company’s stock, valued at approximately $771,761.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $56.37, for a total transaction of $563,700.00. Following the sale, the chief financial officer now directly owns 13,691 shares of the company’s stock, valued at approximately $771,761.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ronald M. Md Kurtz sold 40,000 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the sale, the chief executive officer now directly owns 764,610 shares in the company, valued at approximately $45,991,291.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,000 shares of company stock valued at $4,494,600. 21.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wells Fargo & Company increased their price target on shares of RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. JPMorgan Chase & Co. lifted their price target on RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Needham & Company LLC increased their price objective on RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. BTIG Research upped their price target on shares of RxSight from $61.00 to $72.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, Stifel Nicolaus lifted their price objective on shares of RxSight from $64.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $60.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.